Related stories
Merck Says Keytruda Sales Rose 6% to $8.6 Billion in Q3
Keytruda generated nearly half of Merck’s worldwide sales in the third quarter. Merck attributed the drug’s growth to uptake in earlier-stage indications and its new Qlex form.
M impact | EARNINGS | Oct 29, 2026, 01:30 PM UTC
Merck Executive Expects Moderate Top-Line Growth in 2027
A Merck executive said on a conference call that the company expects moderate top-line growth in 2027.
M impact | EARNINGS | Oct 29, 2026, 01:30 PM UTC
Endovastec Nine-Month Revenue Rises 10.26% to RMB 1.12 Billion
M impact | EARNINGS | Oct 29, 2026, 01:25 PM UTC
Archean Chemical Industries Reports Sept-Quarter Net Profit of 320.6 Million Rupees
M impact | EARNINGS | Oct 29, 2026, 01:24 PM UTC
Merck tops third-quarter forecasts on strong Keytruda and Gardasil results
Merck exceeded forecasts for the third quarter, citing strong results from Keytruda and Gardasil.
M impact | EARNINGS | Oct 29, 2026, 01:24 PM UTC
Coal India Misses Profit View as Costs Rise Amid Strong Demand
Coal India missed profit expectations as costs rose despite strong demand.
M impact | EARNINGS | Oct 29, 2026, 01:23 PM UTC